RWJBarnabas Health and Rutgers Cancer Institute of New Jersey | Strategic Alliance Partners

As New Jersey’s only National Cancer Institute (NCI) – designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey together with RWJBarnabas Health offers the most advanced cancer treatment options including bone marrow transplantation, proton therapy, CAR T-cell therapy and complex surgical procedures. Along with clinical trials and novel therapeutics such as precision medicine and immunotherapy – many of which are not widely available – these cutting-edge therapies are available to adult and pediatric patients. Some of these treatments are fueled by onsite research in which physicians and scientists work side by side to advance our understanding of cancer and transform laboratory discoveries into clinical practice.

Latest from RWJBarnabas Health and Rutgers Cancer Institute of New Jersey


Neil Palmisiano, MD, Appointed as Deputy Director of Phase 1 Therapeutics for Hematologic Malignancies at Rutgers Cancer Institute of New Jersey

October 10, 2022

Further enhancing its focus on providing outstanding, innovative and compassionate care for cancer patients, Rutgers Cancer Institute of New Jersey, the state’s leading cancer center and only NCI-designated Comprehensive Cancer Center together with RWJBarnabas Health, are welcoming a new leader to its team of internationally recognized physicians and researchers.

New Chief of Blood Disorders Named to New Jersey’s Only NCI-Designated Comprehensive Cancer Center

September 15, 2022

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health have appointed Matthew Matasar, MD, MS, as Chief of Blood Disorders at New Jersey’s leading cancer center and the only one in the state designated as a Comprehensive Cancer Center by the National Cancer Institute.

Rutgers Cancer Institute of New Jersey Receives State’s Highest Score in Cancer Specialty

August 10, 2022

Robert Wood Johnson University Hospital, a RWJBarnabas Health facility, has been recognized as one of the top five hospitals in New Jersey and a top 20 Regional Best Hospital in the New York Metropolitan area by U.S. News & World Report in the annual Best Hospitals rankings.

Enhancing Awareness and Participation of Black Breast Cancer Patients in Clinical Trials

August 01, 2022

Coral Omene, MD, PhD, medical oncologist in the Stacy Goldstein Breast Cancer Center at Rutgers Cancer Institute of New Jersey, the state’s only National Cancer Institute-designated Comprehensive Cancer Center together with RWJBarnabas Health, has been awarded a $50,000 grant from the V Foundation for Cancer Research in partnership with ESPN to increase clinical trial awareness and enrollment of Black women with breast cancer.

Rutgers Cancer Institute Research Leader Eileen White Named Rutgers Board of Governors Professor of Molecular Biology and Biochemistry

July 08, 2022

The Rutgers Board of Governors has named Rutgers Cancer Institute of New Jersey Deputy Director Eileen White, PhD, the Board of Governors Professor of Molecular Biology and Biochemistry at the Rutgers School of Arts and Sciences for her contributions to science and leadership in the fields of apoptosis, autophagy and cancer metabolism.

Colon Microbes Provide Clues to Favorable Treatment Options in a Subset of Colon Cancer Patients

June 16, 2022

Investigators from Rutgers Cancer Institute of New Jersey, New Jersey’s only National Cancer Institute-Designated Comprehensive Cancer Center, led a collaborative study to examine the patterns of druggable oncogenic fusions in colon cancer specimens including microsatellite-stable and unstable tumors.

New Chief of Bone Marrow Transplant and Cellular Therapies Named to New Jersey’s Only NCI-Designated Comprehensive Cancer Center

June 08, 2022

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health have appointed Ira Braunschweig, MD, as chief, Section of Transplant and Cell Therapy at Rutgers Cancer Institute, chief of the Transplant and Cell Therapy Service of the RWJBarnabas Health Oncology Service Line, and director for Cell Therapy and Bone Marrow Transplantation at Robert Wood Johnson University Hospital.